Q3 2025 · 13F-HR
Birchview Capital, LPholdings as filed
Filed 2025-11-13 · accession 0001618205-25-000011
$132.4M
Reported value
69
Positions
2025-09-30
Period end
The Brief · Birchview Capital, LP · Q3 2025
AI · grounded in 13F
Birchview Capital, LP established a new position in KLA CORPORATION KLAC valued at $23.6M. The fund also initiated new stakes in BRISTOL-MYERS SQUIBB CO BMY for $14.3M and CORCEPT THERAPEUTICS INC CORT for $5.6M. Additional new positions include PROTHENA CORP PLC PRTA, STOKE THERAPEUTICS INC STOK, and UNIQURE NV QURE.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 482480100 | KLAC | KLA CORPORATION | $23.6M | 17.8% | 21,883 | Common | SOLE |
| 110122108 | BMY | BRISTOL-MYERS SQUIBB CO | $14.3M | 10.8% | 316,842 | Common | SOLE |
| 218352102 | CORT | CORCEPT THERAPEUTICS INC | $5.6M | 4.22% | 67,200 | Common | SOLE |
| G72800108 | PRTA | PROTHENA CORP PLC | $5.4M | 4.05% | 549,019 | Common | SOLE |
| 86150R107 | STOK | STOKE THERAPEUTICS INC | $4.9M | 3.73% | 210,000 | Common | SOLE |
| N90064101 | QURE | UNIQURE NV | $4.6M | 3.47% | 78,728 | Common | SOLE |
| 69047Q102 | OVV | OVINTIV INC | $4.3M | 3.28% | 107,500 | Common | SOLE |
| 64125C109 | NBIX | NEUROCRINE BIOSCIENCES INC | $4.0M | 3.04% | 28,690 | Common | SOLE |
| 004225108 | ACAD | ACADIA PHARMACEUTICALS INC | $3.6M | 2.76% | 171,000 | Common | SOLE |
| 74366E102 | PTGX | PROTAGONIST THERAPEUTICS INC | $3.2M | 2.41% | 48,000 | Common | SOLE |
| 20454B104 | CMPX | COMPASS THERAPEUTICS INC | $3.1M | 2.31% | 872,938 | Common | SOLE |
| 71944F106 | PHR | PHREESIA INC | $2.7M | 2.04% | 114,700 | Common | SOLE |
| 14843C105 | CSTL | CASTLE BIOSCIENCES INC | $2.5M | 1.90% | 110,600 | Common | SOLE |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $2.2M | 1.65% | 78,000 | Common | SOLE |
| 09075X108 | BDSX | BIODESIX INC | $2.2M | 1.63% | 286,804 | Common | SOLE |
| 74838J101 | QDELUSD | QUIDELORTHO CORP | $2.1M | 1.61% | 72,548 | Common | SOLE |
| 05463X106 | AXGN | AXOGEN INC | $2.1M | 1.60% | 119,078 | Common | SOLE |
| 03152W109 | AM6 | AMICUS THERAPEUTICS INC | $2.0M | 1.51% | 253,000 | Common | SOLE |
| 415858109 | HROW | HARROW HEALTH INC | $1.9M | 1.46% | 40,000 | Common | SOLE |
| 26884L109 | EQT | EQT CORPORATION | $1.9M | 1.42% | 34,619 | Common | SOLE |
| 83422E204 | SLDB | SOLID BIOSCIENCES INC | $1.8M | 1.38% | 296,955 | Common | SOLE |
| 68062P106 | OLMA | OLEMA PHARMACEUTICALS INC | $1.7M | 1.29% | 174,000 | Common | SOLE |
| 23282W605 | CYTK | CYTOKINETICS INC | $1.6M | 1.24% | 30,000 | Common | SOLE |
| G01767105 | ALKS | ALKERMES PLC | $1.5M | 1.13% | 50,000 | Common | SOLE |
| 344174107 | FHTX | FOGHORN THERAPEUTICS INC | $1.4M | 1.04% | 281,730 | Common | SOLE |
| G6674U108 | NVCR | NOVOCURE LTD | $1.3M | 1.00% | 102,100 | Common | SOLE |
| 91307C102 | UTHR | UNITED THERAPEUTICS CORP | $1.3M | 0.95% | 3,000 | Common | SOLE |
| 45257U108 | IMNM | IMMUNOME INC | $1.2M | 0.93% | 105,000 | Common | SOLE |
| 574795100 | MASI | MASIMO CORP | $1.2M | 0.92% | 8,280 | Common | SOLE |
| 088786108 | BCYC | BICYCLE THERAPEUTICS PLC | $1.2M | 0.90% | 154,000 | Common | SOLE |
| 89455T109 | TMCI | TREACE MEDICAL CONCEPTS INC | $1.2M | 0.90% | 176,947 | Common | SOLE |
| G5269C101 | — | KINIKSA PHARMACEUTICALS LTD | $1.2M | 0.88% | 30,000 | Common | SOLE |
| 690145107 | OMGBP | OUTSET MEDICAL INC | $1.1M | 0.84% | 78,584 | Common | SOLE |
| 45720N103 | INBX | INHIBRX BIOSCIENCES INC | $1.1M | 0.81% | 31,698 | Common | SOLE |
| 256086109 | DCGO | DOCGO INC | $1.0M | 0.78% | 764,062 | Common | SOLE |
| 45826J105 | NTLA | INTELLIA THERAPEUTICS INC | $1.0M | 0.78% | 60,000 | Common | SOLE |
| 89422G107 | TVTX | TRAVERE THERAPEUTICS INC | $1.0M | 0.78% | 43,060 | Common | SOLE |
| 71722W107 | PHAT | PHATHOM PHARMACEUTICALS INC | $1.0M | 0.76% | 85,000 | Common | SOLE |
| 80706P103 | SRRK | SCHOLAR ROCK HOLDING CORP | $968,240 | 0.73% | 26,000 | Common | SOLE |
| 98420N105 | XENE | XENON PHARMACEUTICALS INC | $843,150 | 0.64% | 21,000 | Common | SOLE |
| 483497103 | KALV | KALVISTA PHARMACEUTICALS INC | $816,060 | 0.62% | 67,000 | Common | SOLE |
| 40637H109 | HALO | HALOZYME THERAPEUTICS INC | $740,734 | 0.56% | 10,100 | Common | SOLE |
| 05464T104 | AXSM | AXSOME THERAPEUTICS INC | $728,700 | 0.55% | 6,000 | Common | SOLE |
| 35671D857 | FCX | FREEPORT-MCMORAN CL-B | $707,689 | 0.53% | 18,044 | Common | SOLE |
| 90400D108 | RARE | ULTRAGENYX PHARMACEUTICAL INC | $661,760 | 0.50% | 22,000 | Common | SOLE |
| 69404D108 | PACB | PACIFIC BIOSCIENCES OF CALIFORNIA INC | $640,000 | 0.48% | 500,000 | Common | SOLE |
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $635,680 | 0.48% | 16,000 | Common | SOLE |
| 05479K106 | ELUT | ELUTIA INC | $633,088 | 0.48% | 711,175 | Common | SOLE |
| 92915B106 | VYGR | VOYAGER THERAPEUTICS INC | $630,067 | 0.48% | 134,918 | Common | SOLE |
| 02081G201 | ATEC | ALPHATEC HOLDINGS INC | $479,820 | 0.36% | 33,000 | Common | SOLE |
| 10806X102 | BBIO | BRIDGEBIO PHARMA INC | $451,255 | 0.34% | 8,688 | Common | SOLE |
| 05338F306 | AVTX | AVALO THERAPEUTICS INC | $394,010 | 0.30% | 31,000 | Common | SOLE |
| 40131M109 | GH | GUARDANT HEALTH INC | $374,880 | 0.28% | 6,000 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $370,433 | 0.28% | 14,847 | Common | SOLE |
| 98937L105 | ZBIO | ZENAS BIOPHARMA INC | $366,300 | 0.28% | 16,500 | Common | SOLE |
| 38341P102 | GOSS | GOSSAMER BIO INC | $363,403 | 0.27% | 138,176 | Common | SOLE |
| 03753U106 | APLSUSD | APELLIS PHARMACEUTICALS INC | $316,820 | 0.24% | 14,000 | Common | SOLE |
| 92332V107 | VTYXUSD | VENTYX BIOSCIENCES INC | $307,352 | 0.23% | 98,827 | Common | SOLE |
| 137404109 | CADL | CANDEL THERAPEUTICS INC | $306,000 | 0.23% | 60,000 | Common | SOLE |
| 68752L100 | KIDS | ORTHOPEDIATRICS CORP | $296,480 | 0.22% | 16,000 | Common | SOLE |
| 872381108 | TELA | TELA BIO INC | $230,950 | 0.17% | 155,000 | Common | SOLE |
| 640268306 | NKTR | NEKTAR THERAPEUTICS | $228,795 | 0.17% | 4,021 | Common | SOLE |
| 81369Y209 | XLV | HEALTHCARE SELECT SECTOR SPDR FUND | $208,477 | 0.16% | 1,498 | Common | SOLE |
| 48576U106 | KPTIEUR | KARYOPHARM THERAPEUTICS INC | $183,022 | 0.14% | 27,985 | Common | SOLE |
| 03828A101 | APLT | APPLIED THERAPEUTICS INC | $136,103 | 0.10% | 225,000 | Common | SOLE |
| 230031106 | CGEM | CULLINAN THERAPEUTICS INC | $118,600 | 0.09% | 20,000 | Common | SOLE |
| N44821101 | IFRX | INFLARX NV | $67,000 | 0.05% | 50,000 | Common | SOLE |
| 022307102 | ALMS | ALUMIS INC | $39,900 | 0.03% | 10,000 | Common | SOLE |
| 98943L107 | ZNTL | ZENTALIS PHARMACEUTICALS INC | $25,670 | 0.02% | 17,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.